Oligometastatic and oligoprogressive esophageal squamous cell carcinoma:clarifying conceptions and surgery perspectives.
10.3760/cma.j.cn112139-20210818-00378
- Author:
Xiao Zheng KANG
1
;
Rui Xiang ZHANG
1
;
Zhen WANG
1
;
Qing Feng ZHENG
1
;
Xian Kai CHEN
1
;
Yong LI
1
;
Jian Jun QIN
1
;
Yin LI
1
Author Information
1. Department of Thoracic Surgery, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
- Publication Type:Journal Article
- MeSH:
Carcinoma, Squamous Cell/surgery*;
Esophageal Neoplasms/surgery*;
Esophageal Squamous Cell Carcinoma;
Esophagectomy;
Humans;
Neoplasm Staging;
Prognosis;
Retrospective Studies
- From:
Chinese Journal of Surgery
2022;60(2):122-127
- CountryChina
- Language:Chinese
-
Abstract:
The oligometastatic and oligoprogressive state has been a hot issue in cancer research. Its indolent tumor behavior, representing a novel therapeutic opportunity, has been identified as a clinical subtype in several malignancies. However, the clinical implications of the oligometastatic and oligoprogressive state in esophageal squamous cell carcinoma (ESCC) have not been thoroughly elucidated. There are still controversies regarding the existence of the oligometastatic state in ESCC, if the solitary regional lymph node metastasis should be viewed as oligoprogressive disease after esophagectomy, and the role of surgery and radiotherapy in ESCC oligometastatic disease. Despite many exciting contributions to the literature on these, further exploration is warranted. Thus, fostering the advance of research and scientific knowledge on the biological and prognostic characteristics scrupulously would facilitate personalizing treatment strategy for better outcomes.
